Xcout Intel
ADAPTIN BIO, INC. competitors & alternatives
The 12 closest competitors and alternatives to ADAPTIN BIO, INC. among biotech companies — ranked by similarity to what ADAPTIN BIO, INC. actually does, not by market-cap band.
Subscribe to see ADAPTIN BIO, INC.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ADAPTIN BIO, INC.
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
ADAPTIN BIO, INC. at a glance
ADAPTIN BIO, INC. is a biotech company headquartered in United States. Xcout tracks 15 named people at ADAPTIN BIO, INC., including Michael J. Roberts (President and Chief Executive Officer).
ADAPTIN BIO, INC. leadership
- Michael J. RobertsPresident and Chief Executive Officer
- Timothy L. Maness, CPAChief Financial Officer
- L. Arthur Hewitt, Ph.D.Chief Development Officer
- Simon Pedder, Ph.D.Executive Chairman
- Michael J. Roberts, Ph.D.Co-Founder and CEO
- L. Arthur HewittExecutive Officer
9 more named people on record for ADAPTIN BIO, INC., with roles, board committees and tenure — see the full roster →
Recent ADAPTIN BIO, INC. news
Top 12 ADAPTIN BIO, INC. competitors
Ranked by semantic similarity — how close each company is to ADAPTIN BIO, INC. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Biotechnology
Q-Immune, Inc. provides real-time protein network analysis for CAR-T cells to predict efficacy, optimize CAR-T design, and improve immunotherapy outcomes. The company serves researchers and developers in oncology, autoimmune, and neuroscience fields by generating data to model and predict cellular behavior.
Biotechnology
Alloy Therapeutics, Inc. is a biotechnology ecosystem company dedicated to democratizing access to antibodies, multispecifics, and genetic modalities, with offices in Waltham and Boston, Massachusetts.
Biotechnology
Matchpoint Therapeutics Inc. discovers and develops precision small molecule medicines utilizing covalent chemistry and chemoproteomics screening to treat immune diseases. The company leverages proprietary screening technologies and machine learning algorithms to expand the druggable proteome and design covalent drug candidates for patients with serious inflammatory and immune conditions.
Biotechnology
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
Biotechnology
Aperture Therapeutics is a biotechnology research company founded in 2022 and headquartered in San Carlos, California. The company is building an innovative drug discovery platform that leverages patient genetic diversity and mechanistic insights.
Biotechnology
Alleo Labs is a precision neuroscience company headquartered in San Francisco, California, that re-engineers the treatment of chronic brain disorders by combining computational biology with brain shuttle technology.
Biotechnology
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Biotechnology
AbbraTech Holdings LLC operates a platform technology focused on recombinant antibody discovery, engineering, and validation. The company targets human diseases such as cancer, immune disorders, and viral infections by developing antibodies for difficult-to-reach drug targets through its proprietary Epivolve technology.
Biotechnology
Amphivena Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in South San Francisco, California. The company specializes in immuno-oncology, developing a platform of dual-function biologics and selective T cell engagers for the treatment of hematological conditions.
Biotechnology
Normunity Holding Company, LLC is a biotechnology company developing novel anti-cancer therapies and biologic medicines, including therapeutic antibodies, bispecific antibodies, and T cell engagers. The company utilizes proprietary discovery platforms originating from a partnership with the Yale School of Medicine to target mechanisms at the interface of tumors and the immune system.
Similar biotech company
AbCellera is a biotechnology company that integrates biology, computation, and engineering to discover and develop antibody-based medicines. The company operates a proprietary technology platform to advance internal and partnered drug programs across therapeutic areas such as endocrinology, immunology, autoimmunity, and oncology.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ADAPTIN BIO, INC. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ADAPTIN BIO, INC.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →